Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01545141
Recruitment Status : Terminated
First Posted : March 6, 2012
Last Update Posted : January 26, 2018
Hemispherx Biopharma
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : April 8, 2016
  Actual Study Completion Date : April 8, 2017